# NxTag respiratory panel v2 gets FDA clearance

written by CAP TODAY
July 15, 2024

July 2024—Diasorin received FDA 510(k) clearance for its NxTag Respiratory Pathogen Panel v2. The updated panel adds SARS-CoV-2 to its mix of 19 viral and two bacterial targets. The updated kit provides enhanced target performance to increase inclusivity and specificity, while improving usability of the product with easier-to-identify plate seals, according to a company press statement. The panel runs on the Magpix system, which tests up to 96 specimens in a single run.

*Diasorin, 562-240-6500*

©2026 CAP TODAY, all rights reserved.